The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).
 
Nicola Hannaway
Research Funding - GlaxoSmithKline
 
Stefania Kassaris
No Relationships to Disclose
 
Janine Marie Davies
Consulting or Advisory Role - Apotex; AstraZeneca; Eisai; Incyte
 
Alannah Smrke
Consulting or Advisory Role - GlaxoSmithKline; Medison; Merck
 
Anna Tinker
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline Canada; Merck Serono
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - GlaxoSmithKline
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - AstraZeneca
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Yvette Drew
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck Serono; Roche Canada (Inst)
Speakers' Bureau - AstraZeneca; Merck Serono
Research Funding - Roche Canada (Inst)
Expert Testimony - Merck Serono